Table 2 Change from baseline to 24Â weeks in glucose parameters
| Â | Â | Baseline | Week 24 | Change | ||
|---|---|---|---|---|---|---|
| Â | Treatment (n) | Mean (SE) | Mean (SE) | Mean (SE) | LS Mean (95% CI) | P-value |
HbA1c (%) | Ezetimibe (n = 69) | 6.94 (0.07) | 7.14 (0.10) | 0.20 (0.06) | 0.22 (0.11, 0.34) | <0.001 |
Placebo (n = 75) | 6.96 (0.06) | 7.09 (0.07) | 0.13 (0.05 | 0.14 (0.03, 0.25) | 0.015 | |
Ezetimibe vs Placebo |  | Difference in LS mean (95% CI) | 0.08 (−0.07, 0.23) | 0.281 | ||
Glyocalbumin (%) | Ezetimibe (n = 69) | 17.16 (0.26) | 17.14 (0.30) | −0.02 (0.17) | −0.02 (−0.37, 0.34) | 0.919 |
Placebo (n = 75) | 17.21 (0.27) | 17.20 (0.29) | −0.01 (0.17) | −0.02 (−0.37, 0.33) | 0.918 | |
Ezetimibe vs Placebo |  | Difference in LS mean (95% CI) | 0.00 (−0.47, 0.47) | 1.000 | ||
Fasting plasma glucose (mg/dL) | Ezetimibe (n = 69) | 124.7 (2.6) | 128.0 (2.8) | 3.3 (3.0) | 6.6 (1.1, 12.1) | 0.019 |
Placebo (n = 75) | 126.7 (2.0) | 135.4 (2.9) | 8.7 (2.5) | 11.4 (6.1, 16.7) | <0.001 | |
Ezetimibe vs Placebo |  | Difference in LS mean (95% CI) | −4.8 (−12.1, 2.5) | 0.194 | ||